Summary "Competitor Landscape: Psoriasis", briefings contain evaluations of ongoing development activities within the psoriasis market, together with analysis of current & potential future product positioning.
Key Highlights from the report - - Certolizumab pegol may find a niche in PsO patients looking to conceive, due to its global approval for use in women of childbearing age - Novartis seeks to identify additional points of differentiation for secukinumab vs. competing biologics by further exploring efficacy and safety in pediatrics and alternative dosing formulations & strategies - BMS-986165 could become the first TYK-2 inhibitor to be approved for PsO, pending positive data from the recently registered Phase III trials
The report comprises five key sections.
Executive Summary: Contains analysis of key market events that have occurred during the previous quarter and which have impacted the Psoriasis landscape.
Landscape Updates - - ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher. - Timeline forecasts for each approved product’s lifecycle management initiatives. - ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies.
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status.
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status.
Appendix - Data slides containing the following information - - Current Early Stage Psoriasis Pipeline & candidate ‘Watch List’. - Timeline Assumptions, including standard assumptions & drug specific assumptions.
Scope - The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov) - Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix - Forecasts are presented in pipeline forecast figures & detailed tables - ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy - Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher - Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market - Reviews ongoing lifecycle management strategies for existing players in the market - A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Our reports have been used by over 10K customers, including:
2019-2023 Competing in the Italy Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities This new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market...
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting,...
Interleukin 1 (IL1) - Pipeline Review, H2 2018 Summary Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of...
Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry Summary Rheumatic disorders are a wide range of conditions which are characterized by chronic pain, with some of the most common conditions being...